TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30334387

Group type: EXPERIMENTAL
Intervention: Left Axis Deviation (LAD) group
Number of subjects: 292

Group type: COMPARATOR
Intervention: Normal Axis group
Number of subjects: 292
Study: 30334521

Group type: EXPERIMENTAL
Intervention: Interferon gamma release assays (IGRAs)
Number of subjects: 10045

Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 10045

Group type: EXPERIMENTAL
Intervention: Combination of tests (TST and IGRAs)
Number of subjects: 10045
Study: 30334527

Group type: EXPERIMENTAL
Intervention: Contrast volume quartile Q1 (≤100 ml)
Number of subjects: 10961

Group type: EXPERIMENTAL
Intervention: Contrast volume quartile Q2 (101-140 ml)
Number of subjects: 10961

Group type: EXPERIMENTAL
Intervention: Contrast volume quartile Q3 (141-200 ml)
Number of subjects: 10961

Group type: EXPERIMENTAL
Intervention: Contrast volume quartile Q4 (>200 ml)
Number of subjects: 10961
Study: 30334909

Group type: EXPERIMENTAL
Intervention: docetaxel 100 mg/m² (n=84)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: doxorubicin 75 mg/m² (n=97)
Number of subjects: 181
Study: 30334942

Group type: EXPERIMENTAL
Intervention: REACH VN intervention (4 core sessions on problem solving, mood management/cognitive restructuring, stress management, and communication, plus up to 2 additional sessions based on caregiver's needs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Enhanced control condition (single session providing verbal and written information on dementia)
Number of subjects: 50
Study: 30335142

Group type: EXPERIMENTAL
Intervention: Survivors of purpura fulminans (PF)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Survivors of septic shock (unexposed group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Amputated patients (n=12/37)
Number of subjects: 37
Study: 30335438

Group type: COMPARATOR
Intervention: BPI
Number of subjects: 287

Group type: COMPARATOR
Intervention: MDD
Number of subjects: 287

Group type: COMPARATOR
Intervention: BPII
Number of subjects: 287

Group type: COMPARATOR
Intervention: ANX
Number of subjects: 287
Study: 30335480

Group type: EXPERIMENTAL
Intervention: Variant near ACVR1B (activin A receptor type 1B)
Number of subjects: 0
Study: 30335559

Group type: EXPERIMENTAL
Intervention: GFF MDI (glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: GFF MDI
Number of subjects: 138
Study: 30335570

Group type: EXPERIMENTAL
Intervention: Primary care-based surveillance
Number of subjects: 0
Study: 30335781

Group type: EXPERIMENTAL
Intervention: EMG pattern recognition (EMG-PR)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Inertial measurement units (IMU)
Number of subjects: 36
Study: 30335787

Group type: EXPERIMENTAL
Intervention: 211At-BC8-B10
Number of subjects: 0
Study: 30336349

Group type: COMPARATOR
Intervention: Bipolar Disorder (BD)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: BPD and BD co-morbidity
Number of subjects: 744

Group type: COMPARATOR
Intervention: Bipolar Disorder (BD) and Healthy Controls (CTRL)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Borderline Personality Disorder (BPD) and ADHD
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: ADHD and BPD
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Traumatic childhood experiences
Number of subjects: 744
Study: 30336478

Group type: EXPERIMENTAL
Intervention: Beam walking under single task conditions (beam walking only)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Beam walking under dual task conditions (beam walking while concurrently performing an arithmetic task)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Fear of falling and fall history reported 6 and 12 months after test 1
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Reliability of beam walking performance retested 7 to 10 days after test 1
Number of subjects: 532
Study: 30336693

Group type: EXPERIMENTAL
Intervention: Sequential afatinib and osimertinib
Number of subjects: 204
Study: 30336704

Group type: EXPERIMENTAL
Intervention: Frustration fMRI paradigm (cued-attention task)
Number of subjects: 195
Study: 30336717

Group type: EXPERIMENTAL
Intervention: High adult activity
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Longer weekday sleep
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Family income >$35,000
Number of subjects: 813

Group type: COMPARATOR
Intervention: Age
Number of subjects: 813

Group type: COMPARATOR
Intervention: Television viewing
Number of subjects: 813

Group type: COMPARATOR
Intervention: Computer use
Number of subjects: 813

Group type: COMPARATOR
Intervention: Stress (adult)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Adult sleep
Number of subjects: 813

Group type: COMPARATOR
Intervention: Child body mass index
Number of subjects: 813

Group type: COMPARATOR
Intervention: Screen time (child)
Number of subjects: 813
Study: 30336814

Group type: EXPERIMENTAL
Intervention: High post-PCI FFR (≥0.84)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: High %FFR increase (>15%)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Low post-PCI FFR (<0.84)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Percent FFR increase with PCI
Number of subjects: 621
Study: 30336823

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) and radiofrequency (RF-)IVUS
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF-)IVUS
Number of subjects: 581
Study: 30336828

Group type: EXPERIMENTAL
Intervention: Congo red staining of tenosynovial tissue
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Cardiac evaluation (biomarkers, electrocardiography, echocardiography with longitudinal strain, technetium pyrophosphate scintigraphy)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Therapy initiation
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Plasma TTR concentration and tetramer kinetic stability
Number of subjects: 98
Study: 30336851

Group type: EXPERIMENTAL
Intervention: Septic shock patients (n=29)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Septic patients (n=6)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-hospitalised subjects (n=9)
Number of subjects: 44
Study: 30337280

Group type: EXPERIMENTAL
Intervention: Reverse Mendelian randomization (MR) approach applied to genetic and biomarker data
Number of subjects: 4147
Study: 30337300

Group type: EXPERIMENTAL
Intervention: Biallelic mutations of the CCAAT/enhancer binding protein α
Number of subjects: 0
Study: 30337314

Group type: COMPARATOR
Intervention: Healthy Newborns (HN)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Newborns from pre-eclamptic women
Number of subjects: 167
Study: 30337358

Group type: EXPERIMENTAL
Intervention: Sotatercept (≥0.1 mg/kg) in non-transfusion-dependent β-thalassemia
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sotatercept (1.0 mg/kg) in transfusion-dependent β-thalassemia
Number of subjects: 46
Study: 30338261

Group type: EXPERIMENTAL
Intervention: IV Ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 0
Study: 30338311

Group type: EXPERIMENTAL
Intervention: Tapioca-based resistant starch type 4 (RS4) in a baked breakfast bar
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard starch in a baked breakfast bar
Number of subjects: 21
Study: 30338508

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30338518

Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block, suprascapular nerve block, and lateral sagittal infraclavicular brachial plexus block (LSIB)
Number of subjects: 23
Study: 30338661

Group type: EXPERIMENTAL
Intervention: Adherence to physician visits (defined as having at least two visits within 14 months after surgical resection)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Adherence to carcinoembryonic antigen (CEA) levels (defined as having at least four CEA levels drawn within 14 months)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Adherence to computed tomography (CT) (defined as completing CT between 10 and 14 months from surgical resection)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Adherence to colonoscopy (defined as completing colonoscopy between 10 and 14 months from surgical resection)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Overall adherence to postresection CRC guideline-recommended care
Number of subjects: 241
Study: 30338903

Group type: EXPERIMENTAL
Intervention: Abnormal ankle-brachial index (ABI)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Toe-brachial index (TBI) and peripheral doppler ultrasound (DUS)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Abnormal ABI
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Artery stenosis assessment
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Assessment of asymptomatic patients with DM1
Number of subjects: 289
Study: 30339323

Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 689

Group type: COMPARATOR
Intervention: Low physical activity
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: High physical activity
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Physical activity levels (low, moderate, high)
Number of subjects: 689
Study: 30339775

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30339784

Group type: EXPERIMENTAL
Intervention: Parental report of children having half their plates filled with FV at dinner
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Child intake of FV
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Children's Healthy Eating Index (HEI)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Parent and child cooking skills and self-efficacy to cook healthy meals
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Family meal frequency
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Availability of more types of fruits and vegetables in the home
Number of subjects: 160
Study: 30339892

Group type: EXPERIMENTAL
Intervention: Combination of tramadol and paracetamol
Number of subjects: 2144

Group type: EXPERIMENTAL
Intervention: Oral morphine
Number of subjects: 2144

Group type: EXPERIMENTAL
Intervention: PONV management guidance after discharge
Number of subjects: 2144

Group type: EXPERIMENTAL
Intervention: Dedicated pain management written protocol
Number of subjects: 2144

Group type: EXPERIMENTAL
Intervention: Standardised take-home analgesic and PONV strategies
Number of subjects: 2144
Study: 30340199

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (5 mg, 10 mg, and 15 mg twice daily)
Number of subjects: 11
Study: 30340460

Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 243
Study: 30340469

Group type: EXPERIMENTAL
Intervention: EUS-FNB using a 20-gauge ProCore needle
Number of subjects: 39
Study: 30340532

Group type: EXPERIMENTAL
Intervention: Intracoronary morphine (1 mg)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 30340539

Group type: EXPERIMENTAL
Intervention: PACE4-FL immunostaining in malignant nodules (n=17)
Number of subjects: 41

Group type: COMPARATOR
Intervention: PACE4-FL immunostaining in benign nodules (n=24)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: PACE4-altCT expression in malignant nodules (n=17)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-lesional thyroid parenchyma
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Specificity of high PACE4-FL immunostaining for malignancy
Number of subjects: 41
Study: 30340583

Group type: EXPERIMENTAL
Intervention: BHOMA intervention
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Normalization Process Theory (NPT)
Number of subjects: 22
Study: 30340648

Group type: EXPERIMENTAL
Intervention: COPD self-management Action Plan intervention delivered by community health workers (CHWs) including COPD education, facilitated self-management Action Plans for COPD exacerbations, and monthly visits by CHWs.
Number of subjects: 240

Group type: COMPARATOR
Intervention: COPD education and facilitated self-management Action Plans for COPD exacerbations.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Quality of life measures using EuroQol-5D (EQ-5D) and St. George's Respiratory Questionnaire (SGRQ) every 3 months over a period of 1 year.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Implementation of COPD Action Plans.
Number of subjects: 240
Study: 30341043

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Weekly motivational emails during the treatment phase
Number of subjects: 1000
Study: 30341050

Group type: EXPERIMENTAL
Intervention: CHW intervention arm
Number of subjects: 300
Study: 30341051

Group type: EXPERIMENTAL
Intervention: Cell phone intervention (smartphone app)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Personal coaching intervention (monthly calls with limited app components)
Number of subjects: 242
Study: 30341052

Group type: EXPERIMENTAL
Intervention: LISA TRACKER
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: IDKmonitor
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Promonitor
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: RIDASCREEN
Number of subjects: 200
Study: 30341136

Group type: EXPERIMENTAL
Intervention: Malaria (asymptomatic)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Malaria (symptomatic)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No malaria
Number of subjects: 240
Study: 30341278

Group type: EXPERIMENTAL
Intervention: hsa-miR-579-3p
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SLC6A2
Number of subjects: 0
Study: 30341664

Group type: EXPERIMENTAL
Intervention: Patient insulin injection technique (IT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nurse insulin injection technique (IT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patient insulin injection technique (IT) score
Number of subjects: 52
Study: 30341681

Group type: EXPERIMENTAL
Intervention: Salt excretion measurement
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Dietary sources of salt intake
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Salt addition at the table
Number of subjects: 94
Study: 30341970

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 3733

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 3733
Study: 30342001

Group type: EXPERIMENTAL
Intervention: Gist Reasoning training
Number of subjects: 32

Group type: COMPARATOR
Intervention: New Learning training
Number of subjects: 32
Study: 30342029

Group type: EXPERIMENTAL
Intervention: Automated polyp detection software (APDS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Endoscopists' detection
Number of subjects: 55
Study: 30342495

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (RT)
Number of subjects: 94
Study: 30342494

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Multimodal prediction model
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patient-tailored approach
Number of subjects: 200
Study: 30342919

Group type: EXPERIMENTAL
Intervention: Intravenous injection of D7-cholesterol
Number of subjects: 2
Study: 30343026

Group type: EXPERIMENTAL
Intervention: Daily co-formulated tenofovir disoproxil fumarate and emtricitabine as HIV PrEP
Number of subjects: 3700
Study: 30343070

Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT) and Cardiac Magnetic Resonance (CMR) with late gadolinium-enhancement (LGE)
Number of subjects: 38
Study: 30343254

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX induction therapy
Number of subjects: 65
Study: 30343526

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (defined as serum 25(OH)D < 10 ng/mL) in ENKTL patients
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency in PTCL patients
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels in ENKTL patients
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels in PTCL patients
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Independent validation cohort (n=115) for ENKTL
Number of subjects: 251
Study: 30343614

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for three cycles before radical cystectomy (RC)
Number of subjects: 50
Study: 30343896

Group type: EXPERIMENTAL
Intervention: PLB-1001 (MET kinase inhibitor)
Number of subjects: 188
Study: 30344012

Group type: COMPARATOR
Intervention: Progressive hemodialysis (HD) starting with one or two sessions per week, increasing frequency based on RRF decline.
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual clinical practice (control group).
Number of subjects: 152
Study: 30344036

Group type: EXPERIMENTAL
Intervention: Assault injury group
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Drug use disorder diagnosis
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Assault injury at baseline
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Community violence exposure
Number of subjects: 511

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 511
Study: 30344063

Group type: EXPERIMENTAL
Intervention: Aspirin and Statins (both drugs)
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Aspirin only
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Statins only
Number of subjects: 1639

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 1639
Study: 30344179

Group type: EXPERIMENTAL
Intervention: Geriatric co-management with proactive consultation for low-risk patients, co-management by geriatric nurse for high-risk patients, and additional medication review for patients with acute geriatric problems.
Number of subjects: 454

Group type: COMPARATOR
Intervention: Usual care (pre-cohort).
Number of subjects: 454
Study: 30344197

Group type: EXPERIMENTAL
Intervention: LEAD Study cohort
Number of subjects: 11423

Group type: EXPERIMENTAL
Intervention: Investigations and measurements in four domains (Lung, hEart, sociAl, boDy)
Number of subjects: 11423

Group type: EXPERIMENTAL
Intervention: Follow-up every four years
Number of subjects: 11423
Study: 30345376

Group type: EXPERIMENTAL
Intervention: Ocular signs or symptoms
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Neurological signs
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Localized ocular pathology
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Concurrent systemic disease
Number of subjects: 696
Study: 30345457

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 30345535

Group type: EXPERIMENTAL
Intervention: SEEG-guided RF-TC
Number of subjects: 296
Study: 30346260

Group type: EXPERIMENTAL
Intervention: Endovascular stroke treatment
Number of subjects: 1662

Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 1662
Study: 30346515

Group type: EXPERIMENTAL
Intervention: TAo-TAVI
Number of subjects: 253
Study: 30346530

Group type: EXPERIMENTAL
Intervention: Parent-led, games-based physical activity intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30346831

Group type: EXPERIMENTAL
Intervention: Intravenous reslizumab
Number of subjects: 321
Study: 30347025

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus nab-paclitaxel
Number of subjects: 33
Study: 30348076

Group type: EXPERIMENTAL
Intervention: XYY syndrome individuals with ASD
Number of subjects: 64

Group type: COMPARATOR
Intervention: XYY syndrome individuals (pre-natally diagnosed)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: XYY syndrome individuals (overall)
Number of subjects: 64
Study: 30348118

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus gemcitabine
Number of subjects: 85
Study: 30348127

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (docetaxel and cyclophosphamide, TC)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 89
Study: 30348216

Group type: EXPERIMENTAL
Intervention: Nivolumab plus Sunitinib (50 mg/day, 4 weeks on/2 weeks off)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Nivolumab plus Pazopanib (800 mg/day)
Number of subjects: 53
Study: 30348224

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 50
Study: 30348537

Group type: EXPERIMENTAL
Intervention: DPYD genotype-guided dosing (initial dose reduction of 25% for c.2846A>T and c.1236G>A carriers, 50% for DPYD*2A and c.1679T>G carriers)
Number of subjects: 1103

Group type: COMPARATOR
Intervention: Standard care (full dose fluoropyrimidine-based therapy)
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing
Number of subjects: 1103

Group type: COMPARATOR
Intervention: Historical cohort (full dose fluoropyrimidine-based therapy)
Number of subjects: 1103
Study: 30348538

Group type: EXPERIMENTAL
Intervention: VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone)
Number of subjects: 268

Group type: COMPARATOR
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 268
Study: 30348618

Group type: EXPERIMENTAL
Intervention: Baseline ALBI score
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Higher ALBI score
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Factors evaluated in multivariate Cox regression analysis
Number of subjects: 1434
Study: 30348638

Group type: EXPERIMENTAL
Intervention: SHR-1210 (anti-PD-1 antibody) and apatinib (VEGFR2 inhibitor) combination therapy
Number of subjects: 43
Study: 30349338

Group type: EXPERIMENTAL
Intervention: LOPI
Number of subjects: 573

Group type: COMPARATOR
Intervention: Armolipid Plus (AP)
Number of subjects: 573
Study: 30349602

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 30349736

Group type: EXPERIMENTAL
Intervention: Modern family planning methods
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Family planning methods
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Counselling about family planning
Number of subjects: 46
Study: 30349845

Group type: EXPERIMENTAL
Intervention: Delafloxacin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparator group (nonquinolone)
Number of subjects: 30